ACHV
NASDAQ · Biotechnology
Achieve Life Sciences Inc
$7.75
+0.21 (+2.79%)
Open$7.50
Previous Close$7.54
Day High$7.84
Day Low$7.35
52W High$8.64
52W Low$2.62
Volume—
Avg Volume1.60M
Market Cap756.85M
P/E Ratio—
EPS$-1.55
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+311.5% upside
Current
$7.75
$7.75
Target
$31.89
$31.89
$22.93
$31.89 avg
$41.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 49.41B | 89.31B | 656.40M |
| Net Income | -122,414,034 | -199,119,158 | 10.36M |
| Profit Margin | -397.8% | -377.9% | 1.6% |
| EBITDA | -122,941,386 | -211,086,782 | 18.53M |
| Free Cash Flow | — | — | 6.70M |
| Rev Growth | -44.7% | -44.7% | +1.9% |
| Debt/Equity | 0.69 | 0.69 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $262.82 | +1.11% | 72.8 | 459.33B |
| AMGN | Amgen Inc | $403.04 | -1.04% | 25.1 | 219.33B |
| GILD | Gilead Sciences Inc | $144.74 | -1.87% | — | 179.15B |
| VRTX | Vertex Pharmaceuticals Inc | $504.73 | -0.40% | 30.1 | 132.51B |
| REGN | Regeneron Pharmaceuticals | $735.20 | +0.05% | 17.4 | 75.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.72 | -4.96% | 36.9 | 29.82B |